Primer: HBM Holdings Limited (2142 HK) - Aug 2026
HBM Holdings is a global biopharmaceutical company with a strong focus on developing innovative antibody therapeutics for immuno-oncology and...
94 Views
APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm
NMPA accepted Sino Bio’s NDA for bispecific ADC drug candidate. FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque...
92 Views
China Healthcare Weekly Wrap (14-18 Sep)
Key news over the week: 1) WCLC cancer conference updates, 2) AI news flows (TuneLab/Genscript, Harbour Bio, ByteDance's Anew Labs), 3)others:...
100 Views
APAC Healthcare Weekly (Sept 13) – Hansoh, InSilico, Shionogi, Kyowa Kirin, Samsung Bio, SK Biopharm
Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review. InSilico initiates rentosertib Phase 3 trial in IPF. Samsung Biologics...
96 Views
China Healthcare Weekly Wrap (7-11 Sep)
1) Insilico AI drug could slow aging indicated by early data; 2) Genscript US$300m placing for AIDD capex; 3) two long-acting TSLP-targeting drugs...
88 Views